FDA Approves Insulet's Omnipod Automated Insulin Delivery System Patients Aged 6 Years & Above

The FDA has cleared Insulet Corporation's PODD Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for patients aged six years of age and older with type 1 diabetes.

  • Omnipod 5 is the first tubeless automated insulin delivery system integrated with the Dexcom G6 Continuous Glucose Monitoring System.
  • It is compatible with a smartphone to adjust insulin and help protect against highs and lows automatically. 
  • The system makes it easier to manage glucose with no multiple daily injections, tubes, or finger sticks.
  • Related: Insulet's Insulin Delivery System Shows Durable Glycemic Control With One Year of Use.
  • SmartAdjust receives a Dexcom CGM value and trend every 5 minutes and predicts glucose levels in 60 minutes. 
  • The system then increases, decreases, or pauses insulin delivery using a customized glucose target, which helps avoid highs and lows in insulin levels.
  • Price Action: PODD shares are up 16.2% at $226.39 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Long IdeasNewsHealth CareFDAMoversTrading IdeasGeneralBriefsType 1 diabetes
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!